Are all estrogens created equal? A review of oral vs. transdermal therapy
- PMID: 22011208
- DOI: 10.1089/jwh.2011.2839
Are all estrogens created equal? A review of oral vs. transdermal therapy
Abstract
Background: To compare oral and transdermal delivery systems in domains of lipid effects; cardiovascular, inflammatory, and thrombotic effects; effect on insulin-like growth factor, insulin resistance, and metabolic syndrome; sexual effects; metabolic effects including weight; and effects on target organs bone, breast, and uterus.
Methods: Review of the literature 1990-2010. Studies selected on basis of applicability, quality of data, and relationship to topic.
Results: Data applicable to the comparisons of oral versus transdermal delivery systems for postmenopausal estrogen therapy were utilized to perform a review and formulate conclusions.
Conclusions: Significant differences appear to exist between oral and transdermal estrogens in terms of hormonal bioavailability and metabolism, with implications for clinical efficacy, potential side effects, and risk profile of different hormone therapy options, but neither results nor study designs are uniform. Bypassing hepatic metabolism appears to result in more stable serum estradiol levels without supraphysiologic concentrations in the liver. By avoiding first-pass metabolism, transdermal hormone therapy may have less pronounced effects on hepatic protein synthesis, such as inflammatory markers, markers of coagulation and fibrinolysis, and steroid binding proteins, while oral hormone therapy has more pronounced hyper-coagulant effects and increases synthesis of C-reactive protein and fibrinolytic markers. Both oral and transdermal delivery systems have beneficial effects on high-density lipoprotein cholesterol to low-density lipoprotein cholesterol ratios (oral>transdermal), while the transdermal system has more favorable effects on triglycerides. Incidence of metabolic syndrome and weight gain appears to be slightly lower with a transdermal delivery system. Oral estrogen's significant increase in hepatic sex hormone binding globulin production lowers testosterone availability compared with transdermal delivery, with clinically relevant effects on sexual vigor.
Similar articles
-
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.Thromb Haemost. 2001 Apr;85(4):619-25. Thromb Haemost. 2001. PMID: 11341495 Clinical Trial.
-
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.Int J Pharm Compd. 2013 Jan-Feb;17(1):74-85. Int J Pharm Compd. 2013. PMID: 23627249
-
Nanoparticle delivery for transdermal HRT.Nanomedicine. 2012 Sep;8 Suppl 1:S83-9. doi: 10.1016/j.nano.2012.05.008. Epub 2012 May 26. Nanomedicine. 2012. PMID: 22640909 Review.
-
Type and route of estrogen administration.Climacteric. 2009;12 Suppl 1:86-90. doi: 10.1080/13697130903007389. Climacteric. 2009. PMID: 19811249 Review.
-
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.Menopause. 2006 Jul-Aug;13(4):643-50. doi: 10.1097/01.gme.0000198485.70703.7a. Menopause. 2006. PMID: 16837886 Clinical Trial.
Cited by
-
Effects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial.J Am Heart Assoc. 2019 Aug 6;8(15):e012763. doi: 10.1161/JAHA.119.012763. Epub 2019 Aug 1. J Am Heart Assoc. 2019. PMID: 31652073 Free PMC article. Clinical Trial.
-
The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males.J Endocr Soc. 2024 Jun 4;8(7):bvae107. doi: 10.1210/jendso/bvae107. eCollection 2024 May 23. J Endocr Soc. 2024. PMID: 38883397 Free PMC article. Review.
-
Estrogen: a master regulator of bioenergetic systems in the brain and body.Front Neuroendocrinol. 2014 Jan;35(1):8-30. doi: 10.1016/j.yfrne.2013.08.001. Epub 2013 Aug 29. Front Neuroendocrinol. 2014. PMID: 23994581 Free PMC article. Review.
-
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.Reprod Biol Endocrinol. 2014 Jul 15;12:66. doi: 10.1186/1477-7827-12-66. Reprod Biol Endocrinol. 2014. PMID: 25023195 Free PMC article.
-
Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.Front Endocrinol (Lausanne). 2021 Mar 26;12:564781. doi: 10.3389/fendo.2021.564781. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33841322 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials